Modulation of mitochondrial function by extracellular acidosis in tumor cells and normal fibroblasts: Role of signaling pathways
Neoplasia. 2024 Apr 16;52:100999. doi: 10.1016/j.neo.2024.100999. Online ahead of print.ABSTRACTIn many tumors pronounced extracellular acidosis resulting from glycolytic metabolism is found. Since several environmental stress factors affect the mitochondrial activity the aim of the study was to analyze the impact of acidosis on cellular oxygen consumption and which signaling pathways may be involved in the regulation. In two tumor cell lines and normal fibroblasts cellular oxygen consumption rate (OCR) and mitochondrial function were measured after 3 h at pH 6.6. Besides the activation of ERK1/2, p38 and PI3K signaling in...
Source: Neoplasia - April 17, 2024 Category: Cancer & Oncology Authors: Carmen Degitz Sarah Reime Christina-Marie Baumbach Mandy Rauschner Oliver Thews Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330]
Neoplasia. 2024 Apr 3;51:100995. doi: 10.1016/j.neo.2024.100995. Online ahead of print.NO ABSTRACTPMID:38574506 | PMC:PMC10997833 | DOI:10.1016/j.neo.2024.100995 (Source: Neoplasia)
Source: Neoplasia - April 4, 2024 Category: Cancer & Oncology Authors: Jae Eun Choi Monique E Verhaegen Sahr Yazdani Rohit Malik Paul W Harms Doris Mangelberger Jean Tien Xuhong Cao Yuping Wang Marcin Cie ślik Jonathan Gurkan Mishaal Yazdani Xiaojun Jing Kristin Juckette Fengyun Su Rui Wang Bing Zhou Ingrid J Apel Shaomeng Source Type: research
Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330]
Neoplasia. 2024 Apr 3;51:100995. doi: 10.1016/j.neo.2024.100995. Online ahead of print.NO ABSTRACTPMID:38574506 | PMC:PMC10997833 | DOI:10.1016/j.neo.2024.100995 (Source: Neoplasia)
Source: Neoplasia - April 4, 2024 Category: Cancer & Oncology Authors: Jae Eun Choi Monique E Verhaegen Sahr Yazdani Rohit Malik Paul W Harms Doris Mangelberger Jean Tien Xuhong Cao Yuping Wang Marcin Cie ślik Jonathan Gurkan Mishaal Yazdani Xiaojun Jing Kristin Juckette Fengyun Su Rui Wang Bing Zhou Ingrid J Apel Shaomeng Source Type: research
Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330]
Neoplasia. 2024 Apr 3;51:100995. doi: 10.1016/j.neo.2024.100995. Online ahead of print.NO ABSTRACTPMID:38574506 | PMC:PMC10997833 | DOI:10.1016/j.neo.2024.100995 (Source: Neoplasia)
Source: Neoplasia - April 4, 2024 Category: Cancer & Oncology Authors: Jae Eun Choi Monique E Verhaegen Sahr Yazdani Rohit Malik Paul W Harms Doris Mangelberger Jean Tien Xuhong Cao Yuping Wang Marcin Cie ślik Jonathan Gurkan Mishaal Yazdani Xiaojun Jing Kristin Juckette Fengyun Su Rui Wang Bing Zhou Ingrid J Apel Shaomeng Source Type: research
Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330]
Neoplasia. 2024 Apr 3;51:100995. doi: 10.1016/j.neo.2024.100995. Online ahead of print.NO ABSTRACTPMID:38574506 | DOI:10.1016/j.neo.2024.100995 (Source: Neoplasia)
Source: Neoplasia - April 4, 2024 Category: Cancer & Oncology Authors: Jae Eun Choi Monique E Verhaegen Sahr Yazdani Rohit Malik Paul W Harms Doris Mangelberger Jean Tien Xuhong Cao Yuping Wang Marcin Cie ślik Jonathan Gurkan Mishaal Yazdani Xiaojun Jing Kristin Juckette Fengyun Su Rui Wang Bing Zhou Ingrid J Apel Shaomeng Source Type: research
Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330]
Neoplasia. 2024 Apr 3;51:100995. doi: 10.1016/j.neo.2024.100995. Online ahead of print.NO ABSTRACTPMID:38574506 | DOI:10.1016/j.neo.2024.100995 (Source: Neoplasia)
Source: Neoplasia - April 4, 2024 Category: Cancer & Oncology Authors: Jae Eun Choi Monique E Verhaegen Sahr Yazdani Rohit Malik Paul W Harms Doris Mangelberger Jean Tien Xuhong Cao Yuping Wang Marcin Cie ślik Jonathan Gurkan Mishaal Yazdani Xiaojun Jing Kristin Juckette Fengyun Su Rui Wang Bing Zhou Ingrid J Apel Shaomeng Source Type: research
Retraction notice to "Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors" [Neoplasia 18 (2016) 347- 355/201]
Neoplasia. 2024 Apr 2;51:100994. doi: 10.1016/j.neo.2024.100994. Online ahead of print.NO ABSTRACTPMID:38569377 | DOI:10.1016/j.neo.2024.100994 (Source: Neoplasia)
Source: Neoplasia - April 3, 2024 Category: Cancer & Oncology Authors: Qian Tan Marina Wang Man Yu Junyan Zhang Robert G Bristow Richard P Hill Ian F Tannock Source Type: research
Preliminary insights on the mutational spectrum of BRCA1 and BRCA2 genes in Pakhtun ethnicity breast cancer patients from Khyber Pakhtunkhwa (KP), Pakistan
Neoplasia. 2024 Mar 26;51:100989. doi: 10.1016/j.neo.2024.100989. Online ahead of print.ABSTRACTGene mutations are a source of genetic instability which fuels the progression of cancer. Mutations in BRCA1 and BRCA2 are considered as major drivers in the progression of breast cancer and their detection indispensable for devising therapeutic and management approaches. The current study aims to identify novel pathogenic and recurrent mutations in BRCA1 and BRCA2 in Pakhtun population from the Khyber Pakhtunkhwa. To determine the BRCA1 and BRCA2 pathogenic mutation prevalence in Pakhtun population from KP, whole exome sequenci...
Source: Neoplasia - March 27, 2024 Category: Cancer & Oncology Authors: Hilal Ahmad Asif Ali Roshan Ali Ali Talha Khalil Ishaq Khan Mah Muneer Khan Mohammed Alorini Source Type: research
Preliminary insights on the mutational spectrum of BRCA1 and BRCA2 genes in Pakhtun ethnicity breast cancer patients from Khyber Pakhtunkhwa (KP), Pakistan
Neoplasia. 2024 Mar 26;51:100989. doi: 10.1016/j.neo.2024.100989. Online ahead of print.ABSTRACTGene mutations are a source of genetic instability which fuels the progression of cancer. Mutations in BRCA1 and BRCA2 are considered as major drivers in the progression of breast cancer and their detection indispensable for devising therapeutic and management approaches. The current study aims to identify novel pathogenic and recurrent mutations in BRCA1 and BRCA2 in Pakhtun population from the Khyber Pakhtunkhwa. To determine the BRCA1 and BRCA2 pathogenic mutation prevalence in Pakhtun population from KP, whole exome sequenci...
Source: Neoplasia - March 27, 2024 Category: Cancer & Oncology Authors: Hilal Ahmad Asif Ali Roshan Ali Ali Talha Khalil Ishaq Khan Mah Muneer Khan Mohammed Alorini Source Type: research
